Keyphrases
Polycystic Ovary Syndrome
100%
Anesthesia
60%
Bone Mineral Density
58%
Ovarian Morphology
56%
Early Diagnosis
50%
Bone Loss
50%
Functional Hypothalamic Amenorrhea
50%
Menstrual Function
50%
Morbidity Risk
50%
Early Treatment
50%
Optimal Energy
50%
Female Athlete Triad
50%
Anti-Mllerian Hormone
50%
Serious Adverse Effects
50%
Hair Removal
50%
Pulsed Laser Diode
50%
Cervical Pregnancy
50%
Cervical Ectopic Pregnancy
50%
3D Ultrasound
50%
Magnetic Resonance Imaging
50%
Operative
50%
Teenagers
50%
Remifentanil
50%
Female Athletes
50%
Estrogen Replacement Therapy
50%
Ultrasonic Resonance
50%
Randomized Clinical Trial
50%
Liraglutide
50%
Clinical Manifestations
50%
Two Dimensional
50%
Energy Availability
50%
Monitored Anesthesia Care
50%
Total Intravenous Anesthesia
50%
Postural Control
50%
Osteoporosis
50%
Ovarian Dysfunction
50%
Laparoscopic Surgery
50%
Eating Disorders
50%
Energy Balance
50%
Day Surgery
50%
Combined Oral Contraceptives
50%
Clinical Conditions
50%
Local Anesthesia
50%
Antral Follicle Count
43%
Sway Area
40%
Transvaginal Ultrasound
37%
Ovarian Volume
31%
Extubation
30%
Sway Velocity
30%
Eye Closure
30%
Medicine and Dentistry
Polycystic Ovary Syndrome
100%
Remifentanil
62%
Athletes
50%
Hair Removal
50%
Methotrexate
50%
Hypothalamic Amenorrhea
50%
Female Athlete Triad
50%
Cervical Pregnancy
50%
Extubation
50%
Ectopic Pregnancy
50%
Laparoscopic Surgery
50%
Magnetic Resonance Imaging
50%
Liraglutide
50%
Total Intravenous Anesthesia
50%
Estrogen Therapy
50%
Vaginal Ultrasonography
50%
Functional Disorder
50%
Morbidity
50%
Ovary Insufficiency
50%
Energy Balance
50%
Osteoporosis
50%
Eating Disorder
50%
Early Diagnosis
50%
Bone Density
50%
Osteolysis
50%
Local Anesthesia
50%
Randomized Clinical Trial
50%
Post-Anesthesia Care Unit
44%
Placebo
25%
Outpatient
25%
Antral Follicle
25%
Obesity
19%
Propofol
19%
